Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 297 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a treatment approach for cancer and other diseases. The company DELigase is an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948, NX-1607 and DeTIL-0255. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B- cell malignancies and potentially autoimmune diseases. Its NX-1607 is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. DeTIL-0255 is a drug-enhanced tumor-infiltrating lymphocyte (TIL) therapy.